New drug combo aims to shield Children's hearts from kawasaki disease

NCT ID NCT07686770

First seen Jul 07, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests whether adding a drug called firsekibart to the standard treatment (IVIG and aspirin) can better prevent coronary artery damage in children with Kawasaki disease. Kawasaki disease causes inflammation in blood vessels, especially those supplying the heart, and can lead to serious heart problems. The trial will enroll 90 children diagnosed within 10 days of fever onset and compare outcomes like coronary artery lesions and fever duration between the two treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
firsekibart (an IL-1β receptor antagonist) plus intravenous immunoglobulin (IVIG) and aspirin
What this could lead to
If successful, this combination could reduce the risk of lasting heart damage in children with Kawasaki disease.
What could go wrong
This is an early exploratory trial with only 90 children, so results may not be conclusive. Adding a new drug also carries unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAWASAKI DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, 201102, China

    Contact

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, 330006, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.